Table 5

Median peripheral blood immune cell counts and indexes at 4 and 6 weeks after ICI initiation according to the early use of steroids

4 weeks6 weeks
Control cohortExposed cohortP value*Control cohortExposed cohortP value*
MedianIQRMedianIQRMedianIQRMedianIQR
WBC†7.526.22–8.948.768.08–12.20<0.0017.756.19–9.738.677.35–11.220.01
ANC†5.003.80–6.207.005.60–9.70<0.0015.153.70–6.907.455.78–8.73<0.001
ALC†1.501.00–1.901.100.80–1.700.071.501.10–1.901.00.70–1.700.004
AMC†0.500.40–0.600.600.50–0.600.080.500.40–0.600.500.40–0.700.82
AEC†0.200.10–0.300.100.10–0.20 0 .009 0.200.10–0.300.100.00–0.20<0.001
REC‡2.601.50–3.801.200.70–3.30<0.0012.351.30–3.901.200.00–2.40<0.001
ABC†0.000.00–0.100.000.00–0.000.460.000.00–0.100.000.00–0.100.61
NLR3.42.4–5.26.93.5–10.6<0.0013.62.4–5.48.13.2–14.6<0.001
dNLR2.01.6–2.83.62.6–4.9<0.0012.21.6–3.04.02.3–5.8<0.001
  • P values below the significance threshold are reported in bold.

  • *Wilcoxon test.

  • †×103.

  • ‡%.

  • ABC, absolute basophil count; AEC, absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; dNLR, derived neutrophil to lymphocyte ratio.ICI, immune checkpoint inhibitor; NLR, neutrophil to lymphocyte ratio; REC, relative eosinophil count; WBC, white blood count;